Aravive announced that the FDA has granted orphan drug designation, or ODD, to batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer, or PDAC.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARAV:
- 2 “Strong Buy” Penny Stocks With Multibagger Potential
- Aravive’s batiraxcept granted orphan designation in pancreatic cancer treatment
- Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium
- Aravive to present positive updated data from ph1 trial of Batiraxcept at ASCO
- Aravive initiated with a Buy at EF Hutton